MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopaminergics"

  • MDS Virtual Congress 2020

    What is holding back apomorphine therapy for Parkinson’s disease? Identifying knowledge gaps amongst Thai neurological medical professionals

    O. Phokaewvarangkul, K. Boonpang, N. Kantachadvanich, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To assess the level of understanding about, and identify knowledge gaps in, apomorphine therapy amongst Thai neurological medical professionals. Background: Continuous subcutaneous apomorphine infusion…
  • MDS Virtual Congress 2020

    Abnormal Cerebral Glucose Metabolism and Dopaminergic Dysfunction in Patients with Parkinson’s Disease with Bilateral Onset

    P. Wu, L. Li, J. Lu, Q. Shi, Y. Zhu, J. Xiao, C. Zuo (Shanghai, China)

    Objective: To explore the characteristics of the abnormal cerebral glucose metabolism and dopamine distribution in patients with Parkinson's disease (PD) with bilateral onset. Background: PD is…
  • MDS Virtual Congress 2020

    Frequency and risk factors of dopamine agonist-induced peripheral edema in patients with Parkinson’s disease

    S. Bostan, N. Durmaz Çelik, S. Özkan (Eskisehir, Turkey)

    Objective: To determine the frequency and risk factors of peripheral edema (PE) development and whether discontinuation of the drug is enough for treatment. To determine…
  • MDS Virtual Congress 2020

    The utility of single dose levodopa challenges in the management of Parkinson’s disease

    D. Tsui, D. Galea, N. Mahant, S. Kim, S. Babu, V. Fung (Sydney, Australia)

    Objective: To retrospectively review the clinical utility of single dose levodopa challenges in the management of Parkinson in a tertiary movement disorder clinic. Background: Acute…
  • 2019 International Congress

    The Dutch Parkinson and Microbiome Study (DUPARM): Gut Microbiome Composition of Treatment-Naïve De Novo Parkinson’s Disease Patients

    J. Boertien, S. Vander Zee, T. van Laar (Groningen, Netherlands)

    Objective: To establish the gut microbiome composition of de novo Parkinson’s disease (PD) patients with no history of dopaminergic medication use. Background: PD is often…
  • 2019 International Congress

    Differential temporal processing across Lewy body disorders and relation to cognitive fluctuations

    E. Matar, J. Phillips, K. Ehgoetz Martens, G. Halliday, S. Lewis (Sydney, Australia)

    Objective: To characterize differences in interval timing between patients with Parkinson’s disease and Dementia with Lewy bodies (DLB) and evaluate their relationship to cognitive fluctuations…
  • 2019 International Congress

    Anxiety and dopaminergic stimulation in patients with Parkinson´s disease.

    A. Camacho Nieto, AR. Franco Salinas, L. Ruiz-Escribano Menchen, MJ. Gallardo Alcañiz, JP. Cabello Rosa, J. Vaamonde Gamo (Ciudad Real, Spain)

    Objective: To report two patients with Parkinson disease and describe the response of this non motor symptom to dopaminergic therapy. Background: Anxiety is frequent comorbidity…
  • 2019 International Congress

    Effect of pill box organizers with alarm on improvement of adherence to pharmacotherapy in patients with Parkinson’s disease: a pilot study

    I. Straka, M. Minár, M. škorvánek, M. Grofik, J. Benetin, P. Valkovič (Bratislava, Slovakia)

    Objective: To find out whether pill box organizers with alarm would improve the rate of adherence in non-adherent patients with Parkinson’s disease (PD) taking three…
  • 2018 International Congress

    Dopaminergics are alternative for the treatment of Bell`s paralysis in acute period

    A. Azimov, R. Sadykov, G. Rakhimbaeva, F. Azimov (Tashkent, Uzbekistan)

    Objective: To study the possibility of using dopaminergic medicines for the treatment of Bell`s paralysis in acute period. Background: In previous reports we conjectured that…
  • 2018 International Congress

    Could the rate of dopaminergic medications reduction affect outcome after STN-DBS?

    S. Alusi (Liverpool, United Kingdom)

    Objective: A retrospective analysis of the rate of dopaminergic drugs reduction following subthalamic nucleus Deep Brain Stimulation (STN-DBS) in a group of Parkinson’s disease patients…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley